Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ICT
MCID: CRC014
MIFTS: 46

Carcinoid Tumors, Intestinal (ICT)

Categories: Cancer diseases, Gastrointestinal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Carcinoid Tumors, Intestinal

About this section

MalaCards integrated aliases for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal 57 13 6
Gastrointestinal Carcinoid Tumor 72 54 70
Carcinoid 72 36 54
Carcinoid Tumor 44 70
Argentaffinoma 72 70
Carcinoid Tumor No Icd-O Subtype 70
Malignant Carcinoid Syndrome 70
Tumor, Carcinoid, Intestinal 39
Carcinoid Tumor of Intestine 70
Intestinal Carcinoid Tumor 72
Ict 72

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant


HPO:

31
carcinoid tumors, intestinal:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 114900
KEGG 36 H00034
MeSH 44 D002276
MedGen 41 C0349535
SNOMED-CT via HPO 68 263681008
UMLS 70 C0007095 C0024586 C0220620 more
Sources

Summaries for Carcinoid Tumors, Intestinal

About this section
KEGG : 36 Carcinoid tumors are relatively uncommon neoplasms that nonetheless comprise up to 85% of neuroendocrine gastrointestinal neoplasms. They most frequently occur in the midgut and develop from neuroendocrine cells that are normally and diffusely present in this location. Most carcinoids are sporadic but epidemiological studies report a familial risk. Moreover, carcinoids can occur within the multiple endocrine neoplasia (MEN) syndrome, a rare familiar tumor syndrome in which mutations in the MEN1 gene are manifested. Recently, it has been shown that a majority (78%) of sporadic carcinoids display loss of heterozygosity for markers around the MEN 1 region, thus suggesting involvement of this gene in the pathogenesis of both familial and sporadic carcinoids.

MalaCards based summary : Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to appendix carcinoid tumor and carcinoid syndrome. An important gene associated with Carcinoid Tumors, Intestinal is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Neuroscience. The drugs lanreotide and Angiopeptin have been mentioned in the context of this disorder. Affiliated tissues include lung, pituitary and liver, and related phenotypes are intestinal carcinoid and digestive/alimentary

UniProtKB/Swiss-Prot : 72 Intestinal carcinoid tumor: A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

More information from OMIM: 114900
Sources

Related Diseases for Carcinoid Tumors, Intestinal

About this section

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1130)
# Related Disease Score Top Affiliating Genes
1 appendix carcinoid tumor 32.1 SYP ENO2 CHGA
2 carcinoid syndrome 32.0 SYP SST MEN1 ENO2 CHGA
3 pulmonary blastoma 31.3 SYP SST NKX2-1 CHGA
4 cystic teratoma 30.9 SYP NKX2-1 ENO2
5 mature teratoma 30.8 SYP ENO2
6 gastritis 30.7 SST GAST CHGA
7 meckel diverticulum 30.7 SYP SST CHGA
8 goblet cell carcinoid 30.6 GAST ENO2 CHGA
9 teratoma 30.5 SYP SST NKX2-1 ENO2 CHGA
10 conn's syndrome 30.5 SST MEN1 CHGA
11 ectopic cushing syndrome 30.5 SST CHGA
12 horseshoe kidney 30.4 SYP NKX2-1 ENO2 CHGA
13 constipation 30.4 SST GAST CHGA
14 appendix adenocarcinoma 30.4 SYP CHGA
15 pernicious anemia 30.3 SST GAST CHGA
16 acromegaly 30.3 SSTR2 SST MEN1
17 ovarian germ cell teratoma 30.3 SYP NKX2-1
18 large cell neuroendocrine carcinoma 30.2 SYP NKX2-1 ENO2 CHGA
19 benign teratoma 30.2 SYP NKX2-1 ENO2 CHGA
20 hyperparathyroidism 30.2 MEN1 GAST CHGA
21 small cell carcinoma 30.1 SYP NKX2-1 GAST ENO2 CHGA
22 ampulla of vater benign neoplasm 30.1 SYP SST ENO2 CHGA
23 atrophic gastritis 30.1 SST MEN1 GAST CHGA
24 lung benign neoplasm 30.1 SYP NKX2-1 ENO2 CHGA
25 granular cell tumor 30.1 SYP NKX2-1 ENO2
26 tubular adenocarcinoma 30.0 SYP ENO2 CHGA
27 pituitary tumors 30.0 SST MEN1
28 autoimmune atrophic gastritis 30.0 GAST CHGA
29 dumping syndrome 30.0 SST GAST
30 thymic carcinoma 29.9 SYP NKX2-1 ENO2
31 ganglioneuroblastoma 29.9 SYP ENO2
32 jejunal neoplasm 29.9 SYP ENO2
33 middle ear adenoma 29.9 SYP ENO2 CHGA
34 gastric antral vascular ectasia 29.9 SST GAST
35 gangliocytoma 29.9 SYP ENO2
36 malignant teratoma 29.9 SYP ENO2
37 mediastinal cancer 29.8 SYP NKX2-1 ENO2 CHGA
38 zollinger-ellison syndrome 29.8 SST MEN1 GAST CHGA
39 extra-adrenal pheochromocytoma 29.8 SYP CHGA
40 mucoepidermoid carcinoma 29.8 NOTCH1 NKX2-1 CHGA
41 neurofibromatosis, type i 29.7 SST MEN1 ENO2
42 lung large cell carcinoma 29.7 SYP NKX2-1 CHGA
43 sertoli-leydig cell tumor 29.7 SYP ENO2
44 small intestine neuroendocrine neoplasm 29.7 SST MEN1
45 primary hyperparathyroidism 29.7 MEN1 GAST CHGA
46 sertoli cell tumor 29.7 SYP ENO2
47 auditory system cancer 29.6 SYP ENO2 CHGA
48 myoblastoma 29.6 SYP ENO2
49 multiple endocrine neoplasia, type i 29.6 SYP SST MEN1 GAST CHGA
50 duodenal somatostatinoma 29.6 SST MEN1 GAST

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:



Diseases related to Carcinoid Tumors, Intestinal
Sources

Symptoms & Phenotypes for Carcinoid Tumors, Intestinal

About this section

Human phenotypes related to Carcinoid Tumors, Intestinal:

31
# Description HPO Frequency HPO Source Accession
1 intestinal carcinoid 31 HP:0006723

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Oncology:
intestinal carcinoid
appendiceal carcinoid
malignant carcinoid of ileum

Clinical features from OMIM®:

114900 (Updated 20-May-2021)

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 GAST MEN1 NKX2-1 NOTCH1 SST SSTR2
2 nervous system MP:0003631 9.28 CHGA CHGB ENO2 MEN1 NKX2-1 NOTCH1
Sources

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

About this section

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
lanreotide Approved Phase 4 108736-35-2
2 Angiopeptin Phase 4
3
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
4
Cyproheptadine Approved Phase 3 129-03-3 2913
5
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
6
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
7
leucovorin Approved Phase 2, Phase 3 58-05-9 6006
8
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 6857599 43805
9
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
11 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
12 3-Iodobenzylguanidine Phase 3
13 Mitogens Phase 3
14 Immunoglobulins Phase 3
15 Immunoglobulins, Intravenous Phase 3
16 Antibodies Phase 3
17 Antibodies, Monoclonal Phase 3
18 Immunoglobulin G Phase 3
19 Endothelial Growth Factors Phase 3
20 Dermatologic Agents Phase 3
21 Anti-Allergic Agents Phase 3
22 Histamine Antagonists Phase 3
23
Histamine Phosphate Phase 3 51-74-1 65513
24 Histamine H1 Antagonists Phase 3
25 Neurotransmitter Agents Phase 3
26 Immunosuppressive Agents Phase 2, Phase 3
27 Angiogenesis Inhibitors Phase 2, Phase 3
28 5-hydroxytryptophan Phase 3
29 Serotonin Receptor Agonists Phase 3
30 Micronutrients Phase 2, Phase 3
31 Antidotes Phase 2, Phase 3
32 Vitamin B9 Phase 2, Phase 3
33 Trace Elements Phase 2, Phase 3
34 Nutrients Phase 2, Phase 3
35 Vitamin B Complex Phase 2, Phase 3
36 Folate Phase 2, Phase 3
37 Protective Agents Phase 2, Phase 3
38 Vitamins Phase 2, Phase 3
39 Hormone Antagonists Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Lactitol Approved, Investigational Phase 1, Phase 2 585-86-4 157355
42
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
45
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
46
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
47
Pancrelipase Approved, Investigational Phase 2 53608-75-6
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
50
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration. Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
2 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
5 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
6 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
7 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
8 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
9 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Completed NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
10 A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues. Completed NCT00690430 Phase 3 Pasireotide;Octreotide
11 Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
12 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
13 Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Not yet recruiting NCT04820751 Phase 3 Cyproheptadine Hydrochloride 4 MG
14 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
15 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
16 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
17 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Withdrawn NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
18 Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
19 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
20 A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
21 Dosimetry-Guided 90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC) Peptide Receptor Radiotherapy (PRRT) in Children & Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors Determined by 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) PET Unknown status NCT02441088 Phase 2 90Y-DOTA-tyr3-Octreotide;Aminosyn II
22 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
23 Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors Completed NCT01396382 Phase 2
24 EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
25 A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
26 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
27 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
28 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
29 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
30 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
31 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
32 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
33 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
34 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
35 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
36 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
37 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Completed NCT02259725 Phase 2 regorafenib
38 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
39 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
40 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
41 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
42 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
43 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
44 A Phase II Study of Axitinib in Advanced Carcinoid Tumors Completed NCT01435122 Phase 2 Axitinib
45 Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid Completed NCT01152827 Phase 2 RAD001
46 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT02575300 Phase 2 Ibrutinib
47 A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
48 A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
49 An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
50 A Single Centre, Pilot Trial of YF476 in Patients With Chronic Atrophic Gastritis, Hypergastrinaemia and Type I Gastric Carcinoids Completed NCT01339169 Phase 2 YF476

Search NIH Clinical Center for Carcinoid Tumors, Intestinal

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Interferon Alfa-2b

Cochrane evidence based reviews: carcinoid tumor

Sources

Genetic Tests for Carcinoid Tumors, Intestinal

About this section
Sources

Anatomical Context for Carcinoid Tumors, Intestinal

About this section

MalaCards organs/tissues related to Carcinoid Tumors, Intestinal:

40
Lung, Pituitary, Liver, Heart, Small Intestine, Kidney, Thyroid
Sources

Publications for Carcinoid Tumors, Intestinal

About this section

Articles related to Carcinoid Tumors, Intestinal:

(show top 50) (show all 568)
# Title Authors PMID Year
1
Complete maternal isodisomy of chromosome 8 in an individual with an early-onset ileal carcinoid tumor. 57
10925383 2000
2
Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. 57
9361035 1997
3
Familial occurrence of metastasizing carcinoid tumors. 57
4694894 1973
4
A familial instance of appendiceal carcinoid. 57
5936207 1966
5
Nuclear translocation of beta-catenin protein but absence of beta-catenin and APC mutation in gastrointestinal carcinoid tumor. 61 54
17009161 2006
6
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. 61 54
15870121 2005
7
Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. 54 61
11559529 2001
8
Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. 61 54
10757334 2000
9
[Gastrointestinal carcinoid tumor--an immunohistochemical and histochemical study]. 54 61
1723678 1991
10
Synchronous Gastrointestinal Carcinoid Tumor and Colon Adenocarcinoma: Case Reports and Literature Review. 61
28584225 2017
11
Bilateral Extraocular Muscle Metastases From a Gastrointestinal Carcinoid Tumor. 61
26767734 2016
12
Metastasis of carcinoid tumor to the transplanted liver graft: a rare case report. 61
24918143 2014
13
Cardiac manifestations of gastrointestinal carcinoid tumor. 61
23834689 2013
14
Costal metastasis: A singular localization of gastrointestinal carcinoid tumor. 61
22558016 2012
15
Metastatic carcinoid disease inducing coronary vasospasm. 61
22412234 2012
16
Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor. 61
21281518 2011
17
Carcinoid tumor metastatic to the tarsal conjunctivae. 61
20724863 2011
18
Prophylactic cholecystectomy in midgut carcinoid patients. 54
20130865 2010
19
PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. 54
20414099 2010
20
Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. 54
20075713 2010
21
Ghrelin's role on gastrointestinal tract cancer. 54
19328680 2010
22
Pure red-cell aplasia as the presenting feature of the carcionoid tumor of the thymus: case report. 54
19224408 2010
23
[Somatostatin receptor scintigraphy in pediatric bronchial carcinoid tumor]. 54
19819594 2010
24
Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. 54
19661786 2010
25
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. 54
19845567 2010
26
MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype. 54
19765735 2010
27
Primary liver carcinoid tumour with a Zollinger Ellison syndrome - an unusual diagnosis: a case report. 54
19918579 2009
28
Primary ovarian carcinoid tumor with luteinized stromal cells. 54
19039598 2009
29
Plasma chromogranin a in patients with inflammatory bowel disease. 54
19090560 2009
30
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature. 54
19523243 2009
31
[A case of small duodenal carcinoid tumor with liver metastasis]. 61
19381058 2009
32
Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. 54
19065104 2009
33
Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. 54
19245907 2009
34
The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. 54
19337629 2009
35
Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). 54
19115524 2009
36
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. 54
19030935 2009
37
Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. 54
19017754 2009
38
Single brain metastasis from a minute, well differentiated, but invading beyond the tunica muscularis mucosa rectal carcinoid. 54
19402375 2009
39
Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. 54
18840995 2009
40
Gastric-and-intestinal mixed endocrine cell phenotypic expression of carcinoid tumors in the rectum. 54
19082450 2009
41
Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary. 54
19047909 2009
42
Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. 54
19149223 2008
43
Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. 54
19088697 2008
44
Metastatic atypical carcinoid tumor of the inferior rectus muscle. 54
19033849 2008
45
Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. 54
18719002 2008
46
Tachykinins in endocrine tumors and the carcinoid syndrome. 54
18524798 2008
47
Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. 54
18655788 2008
48
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. 54
18516757 2008
49
Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract. 54
18430897 2008
50
Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. 54
18448176 2008
Sources

Variations for Carcinoid Tumors, Intestinal

About this section

ClinVar genetic disease variations for Carcinoid Tumors, Intestinal:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SDHD NM_003002.4(SDHD):c.149A>G (p.His50Arg) SNV Uncertain significance 6909 rs11214077 GRCh37: 11:111958677-111958677
GRCh38: 11:112087953-112087953
Sources

Expression for Carcinoid Tumors, Intestinal

About this section
Search GEO for disease gene expression data for Carcinoid Tumors, Intestinal.
Sources

Pathways for Carcinoid Tumors, Intestinal

About this section

Pathways related to Carcinoid Tumors, Intestinal according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.46 SYP NOTCH1 NKX2-1 ENO2
Sources

GO Terms for Carcinoid Tumors, Intestinal

About this section

Biological processes related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oligodendrocyte differentiation GO:0048709 9.37 NOTCH1 NKX2-1
2 neuron fate commitment GO:0048663 9.32 NOTCH1 NKX2-1
3 endoderm development GO:0007492 9.26 NOTCH1 NKX2-1
4 negative regulation of cell proliferation GO:0008285 9.26 SSTR2 SST NOTCH1 MEN1
5 negative regulation of cell-substrate adhesion GO:0010812 9.16 NOTCH1 MEN1
6 forebrain development GO:0030900 8.8 SSTR2 NOTCH1 NKX2-1

Molecular functions related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 SST GAST CHGB
Sources

Sources for Carcinoid Tumors, Intestinal

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....